铁死亡相关基因在膀胱癌中的作用机制研究进展  

Research progress on the mechanism of ferroptosisrelated genes in bladder cancer

作　　者：唐佳佳 范龙梅 黄天渝 左明顺 廖远键 徐特 张能 张江容 TANG Jiajia;FAN Longmei;HUANG Tianyu;ZUO Mingshun;LIAO Yuanjian;XU Te;ZHANG Neng;ZHANG Jiangrong(Department of Urology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,Guizhou Province,China;Nursing School of Zunyi Medical University,Zunyi 563000,Guizhou Province,China)

机构地区：[1]遵义医科大学附属医院泌尿外科,贵州遵义563000 [2]遵义医科大学护理学院,贵州遵义563003

出　　处：《肿瘤》2024年第11期1141-1150,共10页Tumor

基　　金：国家自然科学基金资助项目(8186110524);遵义市科技计划课题项目[遵市科合HZ字(2022)308]

摘　　要：铁死亡是一种铁依赖性细胞死亡形式,与膀胱癌(bladder cancer,BCa)的进展和预后密切相关。其中,铁死亡相关基因(ferroptosis related genes,FRGs)在BCa的生物学效应中发挥重要作用,如参与调节BCa细胞的增殖、迁徙、转移、耐药性、免疫调节和治疗疗效等。此外,FRGs还是预测肿瘤患者预后的重要生物标志物。但是,FRGs在BCa中的具体作用机制目前尚未完全阐明,如何利用FRGs预测BCa的预后并指导BCa的治疗仍在探索阶段。因此,探究FRGs在BCa中的调节和预测作用,对于BCa的治疗尤为重要。本文旨在系统阐述FRGs在BCa发生、发展、治疗和预后中的作用。为进一步探索难治性和耐药性BCa患者的治疗及构建预后风险预测模型等提供一定理论参考依据。Ferroptosis is a form of iron dependent cell death,which is closely related to the progress and prognosis of bladder cancer(BCa).Among them,erroptosis related genes(FRGs)play an important role in the biological effects of BCa,such as participating in regulating the proliferation,migration,metastasis,drug resistance,immune regulation,and therapeutic efficacy of BCa cells.In addition,FRGs are also important biomarkers for predicting the prognosis of tumor patients.However,the specific mechanism of action of FRGs in BCa remains elusive.How to use FRGs to predict the prognosis of BCa and guide the treatment of BCa is still in the exploratory stage.Therefore,exploring the regulatory and predictive role of FRGs in BCa is particularly important for the diagnosis and treatment of BCa.This article aims to systematically elucidate the role of FRGs in the occurrence,development,treatment,and prognosis of BCa.To provide theoretical reference for further exploring the treatment of refractory and drug-resistant BCa patients,and constructing prognostic risk prediction models.

关 键 词：铁死亡 膀胱癌 机制 预后生物标志物 

分 类 号：R737.14[医药卫生—肿瘤]